ReviewJournal of hematology & oncology2023
Gastric cancer treatment: recent progress and future perspectives.
Review in Journal of hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 631 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
631 citing papers in PubMed, 7 syntheses or guidelines pooled it, 843 citations in OpenAlex.
- Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.Cancer medicine · 2026Pooled it
- Sarcopenia Affects the Clinical Efficacy of Immune Checkpoint Inhibitors in Gastric Cancer Patients: a Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Relationship of D-dimer with survival and metastasis in gastric cancer patients: a meta-analysis and systematic review.BMC gastroenterology · 2025Pooled it
- Molecular targets and mechanisms of traditional Chinese medicine combined with chemotherapy for gastric cancer: a meta-analysis and multi-omics approach.Annals of medicine · 2025Pooled it
- Comparative efficacy and safety of distinct PD-1 antibodies in unresectable advanced or recurrent gastric and gastroesophageal junction cancer: a network meta-analysis of randomized controlled trials.BMC gastroenterology · 2025Pooled it
- Pooled it
- Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- High Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.Journal of cachexia, sarcopenia and muscle · 2025Trial
- FTO-mediated mRNA biology · 2026Article
- GLIS3 promotes the malignant biological behavior of gastric cancer cells by transcriptionally regulating PNPO to influence autophagy.Medical oncology (Northwood, London, England) · 2026Article
- Role of lipid-associated fibroblasts and their signature genes FABP4, CD36 and ABCA8 in gastric cancer progression.Oncology letters · 2026Article
- Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review).Oncology reports · 2026Review
- Association of gut microbiota composition and microbe-host interactions with response to chemoimmunotherapy in gastric cancer.Genes and immunity · 2026Article
- Article
- Chemical Stabilization and Transformation of Schiff Base Scaffold: A Path toward Superior Platinum-Based Anti-Cancer Stem Cell Drugs.Journal of medicinal chemistry · 2026Article
- PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype.Journal for immunotherapy of cancer · 2026Article
- Effect of Marital Self-Disclosure Intervention on Fear of Cancer Recurrence and Dyadic Coping Ability Among Gastric Cancer Patients and Their Spouses: A Quasi-Experimental Study.Healthcare (Basel, Switzerland) · 2026Article
- Chronic Stress Promotes Gastric Cancer Metastasis by Inducing Microbiota-Associated Kynurenine Accumulation and Macrophage Remodeling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A novel laparoscopic titanium purse-string forceps: application in animal experiments.Scientific reports · 2026Article
571 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate of regular screening. Systemic therapies for GC, including chemotherapy, targeted therapy and immunotherapy, have evolved significantly in the past few years. For resectable GC, perioperative chemotherapy has become the standard treatment. Ongoing investigations are exploring the potential benefits of targeted therapy or immunotherapy in the perioperative or adjuvant setting. For metastatic disease, there have been notable advancements in immunotherapy and biomarker-directed therapies recently. Classification based on molecular biomarkers, such as programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI), and human epidermal growth factor receptor 2 (HER2), provides an opportunity to differentiate patients who may benefit from immunotherapy or targeted therapy. Molecular diagnostic techniques have facilitated the characterization of GC genetic profiles and the identification of new potential molecular targets. This review systematically summarizes the main research progress in systemic treatment for GC, discusses current individualized strategies and presents future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.